Evidence map›Paper›PMID 40135850›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Fragment Autoantigens Stimulated T-Cell-Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine.

Yuan Li, Huiqin Chen, Qiaofeng Shen, Yingshuang Liu, Pingping Li, Yuqi Ma, Yugang Wang, Shengkai Li, Xueqing Yan, Liyu Liu and 5 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06756295 (A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06756295 early_phase1not yet recruitingnot on this map

A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)

TypeinterventionalSponsorFengming KongRan2025 to 2028Enrolled154ConditionsBreast Cancer, Colorectal Cancer, Melanoma, Lung CancerArmsindividualized tumor FAST vaccine combination (including adjuvant)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuan LiState Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China.
Huiqin ChenWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Qiaofeng ShenWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Yingshuang LiuWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Pingping LiWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Yuqi MaState Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China.
Yugang WangState Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China.
Shengkai LiDepartment of Physics, Princeton University, Princeton, NJ, 08544, USA.
Xueqing YanState Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China.
Liyu LiuWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Jianwei ShuaiWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Min WuWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
Qi OuyangCenter for Quantitative Biology, Peking University, Beijing, 100871, China.
Feng-Ming Spring KongDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, 999077, China.
Gen YangState Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China.ORCID https://orcid.org/0000-0002-0695-5583

Funding

National Key Research and Development Program of China 2019YFF01014402National Key Research and Development Program of China 2023YFC2413200National Key Research and Development Program of China 2023YFC2413201National Natural Science Foundation of China 12375334Shenzhen Science and Technology Program KQTD20180411185028798
6 · The paper itself

Abstract

Tumor cells often down-regulate antigen presentation and mount an immunosuppressive microenvironment, hindering successful cancer immunotherapy and vaccine development. Additionally, due to genomic instability, tumor cells are usually heterogeneous and constantly evolving. Therefore, vaccines need broad antigen coverage and rapid preparation. Here, a personalized whole tumor cell vaccine (TCV), termed fragment autoantigens stimulated T-cell-immunotherapy (FAST) is developed. In 7 h, tumor cells are treated with irradiation and cryoablation. Personalized fragmented antigens (FAs) from these treated cells are used as TCVs. In breast, colon, and melanoma mouse models, FAST achieved significant tumor regression, less metastasis, and longer survival. Notably, FAST outperforms other advanced TCVs, especially in curbing metastasis. Mechanistically, FAs activate efficient, broad-spectrum antigen presentation due to upregulation of immunogenic cell death, MHC-I, and damage-associated molecular patterns. Concurrently, FAST also enhances anti-tumor immunity by reshaping immune microenvironments. Analysis of clinical data shows FAST-associated proteins have prognostic and therapeutic value in patients with liver, stomach, rectal cancers, and melanoma. These results suggest FAST has high anti-tumor efficacy and potential as a personalized TCV platform. The relevant clinical trial NCT06756295 is under initiation with approval of ethics.

Indexed as

AutoantigensCancer VaccinesImmunotherapyT-LymphocytesAnimalsAntigens, NeoplasmCell Line, TumorFemaleHumansMiceTumor MicroenvironmentAntigens, NeoplasmAutoantigensCancer Vaccinesimmunotherapyradiotherapywhole tumor cell vaccines

Identifiers

PMID40135850
PMCPMC12245027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.